181517-99-7

Basic information

• Product Name: 2-{4-[(2-toluidinocarbonyl)amino]phenyl}acetic acid
• Synonyms: 2-{4-[(2-toluidinocarbonyl)amino]phenyl}acetic acid
• CAS NO: 181517-99-7
• Molecular Weight: 284.315
• Mol File: 181517-99-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 210-215 °C (decomp)
• Boiling Point: 389.3±35.0 °C(Predicted)
• Density: 1.331±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-{4-[(2-toluidinocarbonyl)amino]phenyl}acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{4-[(2-toluidinocarbonyl)amino]phenyl}acetic acid(181517-99-7)
• EPA Substance Registry System: 2-{4-[(2-toluidinocarbonyl)amino]phenyl}acetic acid(181517-99-7)

Safety Data

• Hazardous Substances Data: 181517-99-7(Hazardous Substances Data)

Usage

Derivative of acetic acid

2-4-[(2-toluidinocarbonyl)amino]phenylacetic acid is a derivative of acetic acid, meaning that it is a compound that has been modified from the parent compound, acetic acid.

Substituted phenyl group

The molecule contains a substituted phenyl group, which is a benzene ring that has been replaced with other atoms or groups of atoms. In this case, the substituent is a carbonyl and amino functional group.

Amino and carbonyl functional groups

The molecule contains an amino group (-NH2) and a carbonyl group (C=O), which are common functional groups in organic chemistry that can participate in various chemical reactions.

Building block for synthesis

2-4-[(2-toluidinocarbonyl)amino]phenylacetic acid is commonly used as a building block for the synthesis of other organic molecules and pharmaceutical drugs. This means that it can be used as a starting material to create more complex molecules.

Potential applications in materials science and biotechnology

The molecule has potential applications in the fields of materials science and biotechnology, although the specific uses are not specified in the material provided.

Toluidine moiety

The presence of the toluidine group (a methyl-substituted benzene) in the molecule makes it a potentially significant chemical compound with diverse uses in various industries. The toluidine group may confer specific chemical or physical properties that make it useful for certain applications.

Upstream product

• 1197-55-3 4-aminophenylacetic acid 
• 614-68-6 2-tolyl isocyanate 

Downstream Products

• 370596-02-4 C₃₀H₃₄N₄O₅ 
• 353525-12-9 2-{4-[1-(2-toluidinocarbonyl)amino]phenyl}acetyl-L-leucine methyl ester 
• 1426413-17-3 C₇₂H₁₀₇N₁₅O₁₈S 
• 229628-63-1 C₂₄H₂₈N₄O₅ 
• 229628-64-2 C₂₅H₃₂N₄O₅ 
• 229628-80-2 C₂₅H₃₀N₄O₅ 
• 229628-77-7 C₂₉H₃₂N₄O₆ 
• 229628-72-2 C₂₇H₃₂N₆O₅ 
• 229628-75-5 C₂₈H₃₁N₅O₅ 
• 229628-76-6 C₂₅H₃₁N₅O₆ 
• 229629-22-5 C₂₈H₃₁N₅O₅ 
• 229628-62-0 C₂₉H₃₂N₄O₅ 
• 229629-00-9 C₂₆H₃₃N₅O₆ 
• 229628-68-6 C₃₁H₃₆N₄O₅ 

Relevant articles and documents

Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses

Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.

LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in

Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Compounds of Formula (1.0.0): are described wherein A is for example aryl, heteroaryl or heterocyclyl, Y is preferably —C(═O)—; B is independently selected from a group of moieties, the most preferred of which are those of partial Formulas (1.1.2) and (1.1.6): and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH3)2; CF2; or a bridging moiety of partial Formula (1.9.0): where R1ais hydrogen when R1has the meaning of a mono-valent substituent; and R1ais a single bond when R1has the meaning of a di-valent substituent. Said compounds are useful in methods of treating or preventing an inflammatory, autoimmune or respiratory diseases by inhibiting cell adhesion and consequent or associated pathogenic processes subsequently mediated by VLA-4.